financetom
Business
financetom
/
Business
/
Enovis Q4 Adjusted Earnings, Revenue Rise; 2025 Guidance Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Enovis Q4 Adjusted Earnings, Revenue Rise; 2025 Guidance Set
Feb 26, 2025 3:42 AM

06:16 AM EST, 02/26/2025 (MT Newswires) -- Enovis ( ENOV ) reported Q4 adjusted earnings Wednesday of $0.98 per diluted share, up from $0.79 a year earlier.

Analysts polled by FactSet expected $0.92.

Net sales for the quarter ended Dec. 31 was $561 million, up from $455 million a year earlier.

Analysts surveyed by FactSet expected $555.1 million.

The company said it expects 2025 adjusted EPS of $3.10 to $3.25.

Analysts surveyed by FactSet expect $3.16.

Full-year revenue is projected at $2.19 billion to $2.22 billion.

Analysts surveyed by FactSet expect $2.23 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
STERIS to Sell Dental Business to Peak Rock Capital for $787.5 Million in Equity Transaction
STERIS to Sell Dental Business to Peak Rock Capital for $787.5 Million in Equity Transaction
Apr 11, 2024
07:43 AM EDT, 04/11/2024 (MT Newswires) -- STERIS ( STE ) said Thursday it signed a deal to sell its dental business to Peak Rock Capital for $787.5 million in an equity transaction. STERIS ( STE ) said it is eligible for additional earnout of up to $12.5 million from the sale, given that the dental segment reaches certain revenue...
Top Premarket Gainers
Top Premarket Gainers
Apr 11, 2024
07:44 AM EDT, 04/11/2024 (MT Newswires) -- Rallybio Corp. ( RLYB ) shares nearly doubled Thursday premarket after the company said it formed a collaboration with Johnson & Johnson to develop therapies for pregnant women at risk of fetal and neonatal alloimmune thrombocytopenia. Eliem Therapeutics ( ELYM ) shares surged almost 53% on a deal to acquire Tenet Medicines. Alpine...
Vertex Pharmaceuticals' $4.9 Billion Deal for Alpine Shows Lead-Candidate's Potential, Analysts Say
Vertex Pharmaceuticals' $4.9 Billion Deal for Alpine Shows Lead-Candidate's Potential, Analysts Say
Apr 11, 2024
07:43 AM EDT, 04/11/2024 (MT Newswires) -- Vertex Pharmaceuticals' ( VRTX ) deal to acquire Alpine Immune Sciences ( ALPN ) for $4.9 billion shows the strong potential of its lead product in kidney-disease treatment and broader possibilities in other autoimmune illnesses, according to analysts. Vertex said late Wednesday that it will buy Alpine for $65 a share, which RBC...
TransAlta CFO to Retire, To Be Replaced By TC Energy's Joel E. Hunter ; Shares Up 1.3% In US Premarket
TransAlta CFO to Retire, To Be Replaced By TC Energy's Joel E. Hunter ; Shares Up 1.3% In US Premarket
Apr 11, 2024
07:49 AM EDT, 04/11/2024 (MT Newswires) -- TransAlta Corp. ( TAC ) said Thursday that Todd Stack will retire as executive vice-president of finance and chief financial officer of the company, effective June 30. The company's board has tapped Joel Hunter to serve as executive vice president of finance and CFO, effective July 1. Hunter is currently serving as executive...
Copyright 2023-2026 - www.financetom.com All Rights Reserved